Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Accounts Payables (2023 - 2026)

Prelude Therapeutics' Accounts Payables history spans 4 years, with the latest figure at $2.1 million for Q1 2026.

  • On a quarterly basis, Accounts Payables fell 64.52% to $2.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.1 million, a 64.52% decrease, with the full-year FY2025 number at $4.0 million, down 48.49% from a year prior.
  • Accounts Payables hit $2.1 million in Q1 2026 for Prelude Therapeutics, down from $4.0 million in the prior quarter.
  • Over the last five years, Accounts Payables for PRLD hit a ceiling of $7.7 million in Q4 2024 and a floor of $2.1 million in Q1 2026.
  • Historically, Accounts Payables has averaged $4.9 million across 4 years, with a median of $5.1 million in 2024.
  • Biggest five-year swings in Accounts Payables: surged 68.82% in 2024 and later crashed 64.52% in 2026.
  • Tracing PRLD's Accounts Payables over 4 years: stood at $4.6 million in 2023, then soared by 68.82% to $7.7 million in 2024, then tumbled by 48.49% to $4.0 million in 2025, then crashed by 48.05% to $2.1 million in 2026.
  • Business Quant data shows Accounts Payables for PRLD at $2.1 million in Q1 2026, $4.0 million in Q4 2025, and $2.5 million in Q3 2025.